CD274 and hepatocellular carcinoma: A recent clinical trial (IMbrave150) showed that compared with sorafenib or lenvatinib, the combination of atilizumab (PD-L1) and bevacizumab (anti-vascular endothelial growth factor, VEGF) was a better first-line choice for advanced HCC, and the overall survival(OS) of HCC was significantly prolonged (10).